Immunology

Data presented on molecular mechanism of action for HE2000

Published in Proteomics Weekly, April 5th, 2004

Hollis-Eden Pharmaceuticals, Inc., (HEPH) announced the presentation of additional data relating to the molecular mechanism of action by which its immune regulating hormone IMMUNITIN (HE2000) may regulate the immune system back towards homeostasis when used in the treatment of a variety of disease conditions.

The data was presented by Dr. Christopher L. Reading, executive vice president of scientific development of Hollis-Eden, in an oral session at the Strategies for Immune Therapy Meeting in Wuerzburg, Germany.

Immune regulating hormones (IRHs) such as IMMUNITIN have previously been shown in preclinical and early clinical studies to reduce a wide...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Proteomics Weekly

Source: Proteomics Weekly (2004-04-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry